FR2603899A1 - Procede perfectionne pour l'expression de recombinants - Google Patents

Procede perfectionne pour l'expression de recombinants

Info

Publication number
FR2603899A1
FR2603899A1 FR8712633A FR8712633A FR2603899A1 FR 2603899 A1 FR2603899 A1 FR 2603899A1 FR 8712633 A FR8712633 A FR 8712633A FR 8712633 A FR8712633 A FR 8712633A FR 2603899 A1 FR2603899 A1 FR 2603899A1
Authority
FR
France
Prior art keywords
expression
heterologous protein
continuous production
recombinants
eukaryotic host
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR8712633A
Other languages
English (en)
Other versions
FR2603899B1 (fr
Inventor
Cornelia Maxine Gorman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of FR2603899A1 publication Critical patent/FR2603899A1/fr
Application granted granted Critical
Publication of FR2603899B1 publication Critical patent/FR2603899B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Procédé consistant à élaborer un vecteur d'expression ayant une séquence stabilisante en aval d'un promoteur et en amont de l'ADN codant pour une protéine hétérologue dérisée, à effectuer une transfection et à choisir une cellule-hôte eucaryote particulière pour cette expression. Les cellules-hôtes eucaryotes transformées sont cultivées dans des conditions favorables à la production continue de ladite protéine hétérologue. Application : procédé perfectionné d'expression d'un recombinant pour la production continue d'une protéine hétérologue désirée.
FR8712633A 1986-09-12 1987-09-11 Procede perfectionne pour l'expression de recombinants Expired - Lifetime FR2603899B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90718586A 1986-09-12 1986-09-12
US7167487A 1987-07-09 1987-07-09

Publications (2)

Publication Number Publication Date
FR2603899A1 true FR2603899A1 (fr) 1988-03-18
FR2603899B1 FR2603899B1 (fr) 1990-07-13

Family

ID=26752513

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8712633A Expired - Lifetime FR2603899B1 (fr) 1986-09-12 1987-09-11 Procede perfectionne pour l'expression de recombinants

Country Status (9)

Country Link
EP (1) EP0260148A3 (fr)
JP (3) JP2888518B2 (fr)
AU (1) AU613316B2 (fr)
DE (1) DE3730599A1 (fr)
DK (1) DK175363B1 (fr)
FR (1) FR2603899B1 (fr)
GB (1) GB2197321B (fr)
IE (1) IE872455L (fr)
NZ (1) NZ221790A (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341423C (fr) * 1984-10-31 2003-03-04 Paul A. Luciw Proteines recombinantes de virus associes au syndrome d'adenopathie et/ou au syndrome d'immuno-deficience acquise
DE3545126A1 (de) * 1985-12-19 1987-06-25 Boehringer Mannheim Gmbh Verfahren zur verbesserung der expression von eukaryontenprotein
AU613876B2 (en) * 1986-10-01 1991-08-15 Merck & Co., Inc. Synthetic genes encoding proteins from plasmid containing eucaryotic secretory signal peptides and process for secreting encoded proteins
US5024939A (en) * 1987-07-09 1991-06-18 Genentech, Inc. Transient expression system for producing recombinant protein
GB8717430D0 (en) * 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
AU643189B2 (en) * 1988-09-06 1993-11-11 Xoma Corporation Production of chimeric mouse-human antibodies with specificity to human tumor antigens
US5576184A (en) * 1988-09-06 1996-11-19 Xoma Corporation Production of chimeric mouse-human antibodies with specificity to human tumor antigens
DE68924478T2 (de) * 1988-12-13 1996-03-07 Univ Colorado Res Prototypische FeLV-Isolate für die Verwendung als Krankheitsmuster oder Impfstoffe.
JPH02261386A (ja) * 1989-03-31 1990-10-24 Kyowa Hakko Kogyo Co Ltd 組換えベクター
CA2051375C (fr) * 1989-05-04 2000-09-12 Dennis J. Henner Procede et compositions pour l'isolement de la relaxine humaine
CA2018676C (fr) * 1989-06-20 2003-05-06 Christie A. Kelton Methodes de production de proteines heteropolymeriques
SE8903865D0 (sv) * 1989-11-17 1989-11-17 Kabigen Ab Expression of heterologous proteins using eukaryotic cells
US5633076A (en) * 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
GB9027917D0 (en) * 1990-12-21 1991-02-13 Ici Plc Expression systems
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
DK0874057T3 (da) * 1993-06-10 2004-11-22 Bayer Ag Vektor og pattedyrcellelinie med forbedret produktionsevne
GB9408573D0 (en) * 1994-04-29 1994-06-22 Gatsby Charitable Foundation Identification, production and use of saponin gylcosyl hydrolases
US5561053A (en) * 1994-08-05 1996-10-01 Genentech, Inc. Method for selecting high-expressing host cells
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
US5681746A (en) * 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
EP1378525A3 (fr) 1996-06-07 2004-01-14 Neorx Corporation Anticorps humanisés qui se lient à l'antigène relié par l'anticorp NR-LU-13 et leur utilisation dans des méthodes de ciblage
BR9806793A (pt) 1997-01-22 2000-05-16 Univ Texas Processos e composições de fator tissular para coagulação e tratamento de tumores.
US5854021A (en) * 1997-02-28 1998-12-29 Bayer Corporation Enhance protein production method
CA2312291A1 (fr) 1997-12-05 1999-06-17 The Immune Response Corporation Vecteurs et genes a expression accrue
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
AU750414B2 (en) 1998-07-13 2002-07-18 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US6051401A (en) * 1998-07-28 2000-04-18 Bayer Corporation Methods and constructs for protein expression
US7399751B2 (en) * 1999-11-04 2008-07-15 Sertoli Technologies, Inc. Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
FR2823222B1 (fr) 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
MXPA05003049A (es) 2002-09-19 2005-11-17 Us Gov Health & Human Serv Polipeptidos de phlebotomus ariasi, polipeptidos de phlebotomus perniciosus y metodos de uso.
EP1572968B1 (fr) 2002-10-29 2009-04-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polypeptides de lutzomyia longipalpis et methodes d'utilisation desdits polypeptides
EP1594537B1 (fr) 2003-02-19 2012-10-24 Merial Vaccination ou immunisation utilisant un schema posologique de double administration d'amor age et de rappel contre le vrs, le virus-herpes bovin 1, le virus bvd, le virus de parainfluenza bovin de type 3
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
US20080312143A1 (en) * 2003-10-16 2008-12-18 Zlb Behring Gmbh Modified Cdna for High Expression Levels of Factor VIII and Its Derivatives
RS51324B (sr) 2005-04-25 2010-12-31 Merial Ltd. Vakcine protiv nipah virusa
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
US7598364B2 (en) 2005-11-14 2009-10-06 Merial Limited Plasmid encoding canine BMP-7
BRPI0709282B8 (pt) 2006-03-29 2021-05-25 Merial Ltd vacina contra estreptococos
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
SI2147105T1 (sl) 2007-05-02 2013-08-30 Merial Limited DNA-plazmidi z izboljšano ekspresijo in stabilnostjo
EP2283035B1 (fr) 2008-05-08 2015-07-29 Merial Limited Vaccin contre la leishmaniose utilisant un immunogène salivaire de phlébotome
MX2011005604A (es) 2008-11-28 2011-09-01 Merial Ltd Vacuna recombinante para influenza aviar y sus usos.
CN102428099B (zh) 2009-04-03 2016-03-16 梅里亚有限公司 运载新城疫病毒的禽疫苗
ES2600612T3 (es) 2009-05-22 2017-02-10 Merial, Inc. Plásmido libre de antibióticos
US20110236416A1 (en) 2010-03-12 2011-09-29 Jean-Christophe Audonnet Foot and mouth disease virus recombinant vaccines and uses thereof
JP5913316B2 (ja) 2010-08-31 2016-04-27 メリアル リミテッド ニューカッスル病ウイルスをベクターとするヘルペスウイルスワクチン
US9216213B2 (en) 2011-04-20 2015-12-22 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
CA2837375C (fr) 2011-06-01 2019-07-16 Merial Limited Administration sans aiguille de vaccins contre le vsrrp
LT2734230T (lt) 2011-07-20 2019-03-25 Merial Limited Rekombinantinė kačių leikemijos viruso vakcina, turinti optimizuotą kačių leukemijos viruso apvalkalo geną
CA2867893C (fr) 2012-03-20 2022-09-20 Merial Limited Vaccin contre l'herpesvirus equin 1 recombinant contenant une glycoproteine c mutee et utilisations associees
RU2656187C2 (ru) 2012-06-13 2018-05-31 Мериал, Инк. Реассортантные btv и ahsv вакцины
RU2500817C1 (ru) * 2012-07-19 2013-12-10 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК рВК415, КОДИРУЮЩАЯ ПОЛИПЕПТИД РЕКОМБИНАНТНОГО ТКАНЕВОГО АКТИВАТОРА ПЛАЗМИНОГЕНА ЧЕЛОВЕКА, ЛИНИЯ КЛЕТОК Cricetulus griseus CHO 1F8 - ПРОДУЦЕНТ РЕКОМБИНАНТНОГО ТКАНЕВОГО АКТИВАТОРА ПЛАЗМИНОГЕНА ЧЕЛОВЕКА И СПОСОБ ПОЛУЧЕНИЯ И ВЫДЕЛЕНИЯ ПОЛИПЕПТИДА, ОБЛАДАЮЩЕГО АКТИВНОСТЬЮ ТКАНЕВОГО АКТИВАТОРА ПЛАЗМИНОГЕНА
WO2015123307A1 (fr) 2014-02-11 2015-08-20 University Of Miami Procédés et compositions pour l'expression d'un transgène dans un système de vecteur du virus de l'herpès
WO2016073410A1 (fr) 2014-11-03 2016-05-12 Merial, Inc. Procédés d'utilisation de formulations de vaccin par micro-aiguilles pour éliciter une immunité de protection contre le virus de la rage chez les animaux
BR112017027895A2 (pt) 2015-06-23 2018-11-06 Merial Inc vetores virais recombinantes contendo proteínas menores de prrsv e métodos de fabricação e utilização destes
MX2018002112A (es) 2015-08-20 2019-03-28 Merial Inc Vacunas recombinantes contra el calicivirus felino (fcv) y sus usos.
EP4286002A3 (fr) 2015-09-29 2024-02-28 Boehringer Ingelheim Animal Health USA Inc. Vaccins à particules pseudo-virales (vlp) de parvovirus canin (cpv) et utilisations associées
DK3380119T3 (da) 2015-11-23 2021-11-15 Boehringer Ingelheim Animal Health Usa Inc Fmdv- og e2-fusionsproteiner og anvendelser deraf
TWI760322B (zh) 2016-01-29 2022-04-11 美商百靈佳殷格翰動物保健美國有限公司 重組腺病毒載體裝載之fmdv疫苗及其用途
JP7287611B2 (ja) * 2018-02-07 2023-06-06 学校法人日本医科大学 改良型アデノ随伴ウイルスベクター

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986003520A1 (fr) * 1984-12-04 1986-06-19 Genetics Institute, Inc. Methode de production de l'erythropoietine
EP0173177B1 (fr) * 1984-08-24 1992-04-22 BEHRINGWERKE Aktiengesellschaft Séquences stimulantes pour systèmes d'expression eucaryotiques

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI86885C (fi) * 1984-04-20 1992-10-26 Genentech Inc Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173177B1 (fr) * 1984-08-24 1992-04-22 BEHRINGWERKE Aktiengesellschaft Séquences stimulantes pour systèmes d'expression eucaryotiques
WO1986003520A1 (fr) * 1984-12-04 1986-06-19 Genetics Institute, Inc. Methode de production de l'erythropoietine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GENE, vol. 45, no. 1, octobre 1986, pages 101-105, Elsevier Science Publishers B.V. (Biomedical Division), Amsterdam, NL; M.K. FOECKING et al.: "Powerful and versatile enhancer-promoter unit for mammalian expression vectors" *
JOURNAL OF VIROLOGY, vol. 56, no. 1, octobre 1985, pages 135-143, American Society for Microbiology, US; R.R. SPAETE et al.: "Regulation of cytomegalovirus gene expression: alpha and beta promoters are trans activated by viral functions in permissive human fibroblasts" *

Also Published As

Publication number Publication date
DK175363B1 (da) 2004-09-13
JPH09103296A (ja) 1997-04-22
JP3148121B2 (ja) 2001-03-19
AU613316B2 (en) 1991-08-01
FR2603899B1 (fr) 1990-07-13
JPS63152986A (ja) 1988-06-25
IE872455L (en) 1988-03-12
DK473987A (da) 1988-03-13
JP2888518B2 (ja) 1999-05-10
DK473987D0 (da) 1987-09-11
DE3730599A1 (de) 1988-07-07
EP0260148A2 (fr) 1988-03-16
GB2197321A (en) 1988-05-18
NZ221790A (en) 1990-07-26
EP0260148A3 (fr) 1989-06-07
GB2197321B (en) 1990-10-03
GB8721424D0 (en) 1987-10-21
AU7831787A (en) 1988-05-19
JP2000308497A (ja) 2000-11-07

Similar Documents

Publication Publication Date Title
FR2603899A1 (fr) Procede perfectionne pour l'expression de recombinants
Gilley et al. Autonomous replication and addition of telomerelike sequences to DNA microinjected into Paramecium tetraurelia macronuclei
Adelman et al. In vitro deletional mutagenesis for bacterial production of the 20,000-dalton form of human pituitary growth hormone.
Hudziak et al. Establishment of mammalian cell lines containing multiple nonsense mutations and functional suppressor tRNA genes
Laban et al. Transfection of Leishmania enriettii and expression of chloramphenicol acetyltransferase gene.
Yost et al. Translation of unspliced transcripts after heat shock
Müller‐Newen et al. Enoyl‐CoA hydratase and isomerase form a superfamily with a common active‐site glutamate residue
Folk et al. A detailed mutational analysis of the eucaryotic tRNA1met gene promoter
ES2046177T3 (es) Construccion de una proteina enlazante a igg para facilitar el tratamiento aguas abajo utilizando ingenieria de proteinas.
NO175216C (no) Fremgangsmåte for fremstilling av human vevs-plasminogen-aktivator, DNA sekvens, replikerbar ekspresjonsvektor og cellekultur
WO1991005866A1 (fr) Nouveaux systemes d'expression utilisant des promoteurs de bacteriophage t7 et des sequences de gene
Drabkin et al. Amber suppression in mammalian cells dependent upon expression of an Escherichia coli aminoacyl-tRNA synthetase gene
DE3851309D1 (de) Transfizierte Zellstämme, die den menschlichen Rhinovirus-Hauptrezeptor exprimieren.
Lin et al. Extrachromosomal recombination in mammalian cells as studied with single-and double-stranded DNA substrates
McCarthy Expression of the unc genes in Escherichia coli
Ze-guo et al. A simple and rapid nucleotide sequencing strategy and its application in analyzing a rice histone 3 gene
Sacerdot et al. Both forms of translational initiation factor IF2 (α and β) are required for maximal growth of Escherichia coli: evidence for two translational initiation codons for IF2β
Yagi et al. Complete restoration of normal DNA repair characteristics in group F xeroderma pigmentosum cells by over-expression of transfected XPF cDNA.
Chen et al. A puhA gene deletion and plasmid complementation system for facile site directed mutagenesis studies of the reaction center H protein of Rhodobacter sphaeroides
Cooley et al. Transcription factor binding is limited by the 5′-flanking regions of a Drosophila tRNAHis gene and a tRNAHis pseudogene
EP0457527A1 (fr) Plasmides, cellules animales transformées et procédé pour la production de protéine étrangère
EP0179786A1 (fr) Vecteurs d'expression a nombre de reproduction eleve.
Lukacsovich et al. The structural basis of the high in vivo strength of the rRNA P2 promoter of Escherichia coli
Berezowsky et al. Slow troponin C is present in both muscle and nonmuscle cells
Romeo et al. Determinants of an unusually stable mRNA in the bacterium Myxococcus xanthus